Tilray Brands, Inc. (TLRY)
USD 0.46
(-6.26%)
USD 0.46
(-6.26%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 | -174.74 Million USD | 87.24% |
| 2023 | -1.36 Billion USD | -993.5% |
| 2022 | 153.29 Million USD | 3198.75% |
| 2021 | -4.94 Million USD | -109.61% |
| 2020 | 51.48 Million CAD | 2080.58% |
| 2019 | -2.59 Million CAD | 73.03% |
| 2018 | -9.63 Million CAD | -832.8% |
| 2017 | -1.03 Million CAD | -23.56% |
| 2016 | -836.22 Thousand CAD | 69.39% |
| 2015 | -2.73 Million CAD | -5926.43% |
| 2014 | -45.33 Thousand CAD | 53.98% |
| 2013 | -98.51 Thousand CAD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 FY | -112.75 Million USD | 91.77% |
| 2024 Q1 | -34.36 Million USD | 61.81% |
| 2024 Q2 | -41.75 Million USD | -21.53% |
| 2024 Q3 | -33.39 Million USD | 20.03% |
| 2024 Q4 | -20.59 Million USD | 38.32% |
| 2023 Q4 | -89.98 Million USD | 92.54% |
| 2023 Q3 | -1.2 Billion USD | -2648.08% |
| 2023 FY | -1.36 Billion USD | -993.5% |
| 2023 Q1 | -33.33 Million USD | -112.41% |
| 2023 Q2 | -43.91 Million USD | -31.73% |
| 2022 Q3 | 13.02 Million USD | 123.81% |
| 2022 Q4 | 268.52 Million USD | 1962.12% |
| 2022 FY | 153.29 Million USD | 3198.75% |
| 2022 Q2 | -54.68 Million USD | 20.21% |
| 2022 Q1 | -68.53 Million USD | 7.01% |
| 2021 Q4 | -73.69 Million USD | -37.46% |
| 2021 Q1 | 15.85 Million CAD | 131.77% |
| 2021 Q2 | -33.27 Million CAD | -309.91% |
| 2021 Q3 | -53.61 Million CAD | -61.11% |
| 2021 FY | -4.94 Million USD | -109.61% |
| 2020 Q3 | 6.5 Million CAD | 190.4% |
| 2020 FY | 51.48 Million CAD | 2080.58% |
| 2020 Q1 | 2.98 Million CAD | 119.76% |
| 2020 Q4 | -49.89 Million CAD | -866.94% |
| 2020 Q2 | -7.19 Million CAD | -340.87% |
| 2019 Q3 | -67.89 Million CAD | -318.21% |
| 2019 Q2 | -16.23 Million CAD | -103.69% |
| 2019 Q1 | -7.96 Million CAD | -19.65% |
| 2019 FY | -2.59 Million CAD | 73.03% |
| 2019 Q4 | -15.12 Million CAD | 77.73% |
| 2018 Q1 | 1.09 Million CAD | -27.53% |
| 2018 Q3 | -3.16 Million CAD | -255.04% |
| 2018 Q4 | -6.66 Million CAD | -110.68% |
| 2018 FY | -9.63 Million CAD | -832.8% |
| 2018 Q2 | -890.51 Thousand CAD | -181.24% |
| 2017 Q3 | -3.51 Million CAD | -1070.05% |
| 2017 Q4 | 1.51 Million CAD | 143.07% |
| 2017 FY | -1.03 Million CAD | -23.56% |
| 2017 Q1 | 601.82 Thousand CAD | 1734.07% |
| 2017 Q2 | 362.01 Thousand CAD | -39.85% |
| 2016 Q1 | -396.13 Thousand CAD | 12.0% |
| 2016 FY | -836.22 Thousand CAD | 69.39% |
| 2016 Q4 | -36.82 Thousand CAD | 40.42% |
| 2016 Q3 | -61.81 Thousand CAD | 82.6% |
| 2016 Q2 | -355.2 Thousand CAD | 10.33% |
| 2015 Q2 | -6482.23 CAD | 22.05% |
| 2015 Q1 | -8316.12 CAD | 86.85% |
| 2015 FY | -2.73 Million CAD | -5926.43% |
| 2015 Q4 | -450.17 Thousand CAD | -20.78% |
| 2015 Q3 | -372.72 Thousand CAD | -5650.01% |
| 2014 Q1 | -7855.65 CAD | -73.67% |
| 2014 Q3 | -47.23 Thousand CAD | -933.36% |
| 2014 Q4 | -63.26 Thousand CAD | -33.93% |
| 2014 FY | -45.33 Thousand CAD | 53.98% |
| 2014 Q2 | -4571.06 CAD | 41.81% |
| 2013 FY | -98.51 Thousand CAD | 0.0% |
| 2013 Q2 | -20.45 Thousand CAD | -49.81% |
| 2013 Q3 | -13.33 Thousand CAD | 34.84% |
| 2013 Q4 | -4523.23 CAD | 66.07% |
| 2013 Q1 | -13.65 Thousand CAD | 24.11% |
| 2012 Q2 | -3424.37 CAD | 0.0% |
| 2012 Q3 | -65.73 Thousand CAD | -1819.75% |
| 2012 Q4 | -17.99 Thousand CAD | 72.63% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Esperion Therapeutics, Inc. | -155.56 Million USD | -12.331% |
| Theratechnologies Inc. | -10.62 Million USD | -1544.349% |
| Safety Shot Inc | -12.18 Million USD | -1334.199% |
| Cosmos Health Inc. | -21.83 Million USD | -700.436% |
| Cronos Group Inc. | -81.37 Million USD | -114.739% |
| Ironwood Pharmaceuticals, Inc. | 209.03 Million USD | 183.596% |
| Kala Pharmaceuticals, Inc. | -39.15 Million USD | -346.313% |
| Organogenesis Holdings Inc. | 12.52 Million USD | 1495.17% |
| Universe Pharmaceuticals INC | -3.52 Million USD | -4854.811% |
| ProPhase Labs, Inc. | -21.61 Million USD | -708.518% |
| Sonoma Pharmaceuticals, Inc. | -4.7 Million USD | -3617.188% |
| Dynavax Technologies Corporation | -37.02 Million USD | -371.927% |
| Radius Health, Inc. | -3.92 Million USD | -4352.102% |
| China SXT Pharmaceuticals, Inc. | -2.51 Million USD | -6847.512% |
| Alvotech | -354.86 Million USD | 50.757% |
| Sunshine Biopharma, Inc. | -4.78 Million USD | -3551.705% |
| Alpha Teknova, Inc. | -35.56 Million USD | -391.367% |
| Intra-Cellular Therapies, Inc. | -159.38 Million USD | -9.64% |
| SCYNEXIS, Inc. | 72.66 Million USD | 340.467% |
| Harrow Health, Inc. | 580 Thousand USD | 30228.448% |
| Biofrontera Inc. | -22.67 Million USD | -670.583% |
| DURECT Corporation | -36.88 Million USD | -373.769% |
| Supernus Pharmaceuticals, Inc. | -5.26 Million USD | -3216.474% |
| ANI Pharmaceuticals, Inc. | 46.97 Million USD | 472.027% |
| OptiNose, Inc. | -22.74 Million USD | -668.177% |
| RedHill Biopharma Ltd. | 12.63 Million USD | 1483.352% |
| Aquestive Therapeutics, Inc. | -15.1 Million USD | -1057.098% |
| Cumberland Pharmaceuticals Inc. | -6.21 Million USD | -2713.558% |
| SIGA Technologies, Inc. | 83.62 Million USD | 308.972% |
| Lifecore Biomedical, Inc. | 9.33 Million USD | 1972.736% |
| Shineco, Inc. | -17.06 Million USD | -923.944% |
| Phibro Animal Health Corporation | 53.31 Million USD | 427.76% |
| Procaps Group S.A. | 52.32 Million USD | 433.967% |
| TherapeuticsMD, Inc. | -8.52 Million USD | -1950.276% |
| Regencell Bioscience Holdings Limited | -4.73 Million USD | -3589.152% |
| Viatris Inc. | 766.2 Million USD | 122.807% |
| Sunshine Biopharma, Inc. | -4.78 Million USD | -3551.705% |
| Rockwell Medical, Inc. | -6.67 Million USD | -2519.865% |
| Incannex Healthcare Limited | -30.04 Million USD | -481.688% |
| Aytu BioPharma, Inc. | -5.25 Million USD | -3225.942% |
| Collegium Pharmaceutical, Inc. | 166.96 Million USD | 204.662% |
| PetIQ, Inc. | 60.01 Million USD | 391.169% |
| Silver Spike Investment Corp. | 7.34 Million USD | 2480.686% |
| Neurocrine Biosciences, Inc. | 250.9 Million USD | 169.647% |
| Journey Medical Corporation | -2.07 Million USD | -8329.571% |
| Alimera Sciences, Inc. | -1.47 Million USD | -11779.334% |
| Petros Pharmaceuticals, Inc. | -13.61 Million USD | -1183.251% |
| Assertio Holdings, Inc. | -243.53 Million USD | 28.247% |
| Shuttle Pharmaceuticals Holdings, Inc. | -5.89 Million USD | -2865.61% |
| Embecta Corp. | 221.5 Million USD | 178.892% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | -771.544% |
| Procaps Group, S.A. | 38.97 Million USD | 548.375% |
| PainReform Ltd. | -9.58 Million USD | -1723.299% |
| Avadel Pharmaceuticals plc | -137.84 Million USD | -26.766% |
| Hempacco Co., Inc. | -8.81 Million USD | -1882.971% |
| Talphera, Inc. | -16.88 Million USD | -934.668% |
| Pacira BioSciences, Inc. | 87.67 Million USD | 299.31% |
| Alvotech | -354.86 Million USD | 50.757% |
| Lantheus Holdings, Inc. | 364.64 Million USD | 147.922% |
| Kamada Ltd. | 10.06 Million USD | 1836.337% |
| Indivior PLC | -4 Million USD | -4268.625% |
| Currenc Group, Inc. | -6.64 Million USD | -2529.411% |
| Evoke Pharma, Inc. | -7.43 Million USD | -2251.602% |
| Flora Growth Corp. | -50.35 Million USD | -247.033% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | -771.544% |
| Evolus, Inc. | -49.23 Million USD | -254.935% |
| HUTCHMED (China) Limited | 18.37 Million USD | 1050.993% |
| Amphastar Pharmaceuticals, Inc. | 196.98 Million USD | 188.709% |
| Akanda Corp. | -10.05 Million USD | -1638.519% |